Drug Profile
Research programme: respiratory tract disorder therapeutics - Tris Pharma/Vernalis
Alternative Names: CCP-05; CCP-06; Cough/cold therapeutics - Tris Pharma/VernalisLatest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Developer Tris Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Common cold; Cough
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 28 Jul 2018 No recent reports of development identified for preclinical development in Common cold in USA (PO, Controlled release)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cough in USA (PO, Controlled release)